Neoadjuvant Anti-PD-1 Strategy Prevails Over Adjuvant in Resectable Melanoma

(MedPage Today) -- PARIS -- The randomized trial data have spoken, and they favor neoadjuvant immunotherapy over adjuvant treatment for resectable melanoma. Neoadjuvant pembrolizumab (Keytruda) followed by surgery and additional pembrolizumab...
Source: MedPage Today Hematology/Oncology - Category: Hematology Source Type: news